Additionally, a new form of immunotherapy that involves a bispecific CD3 T cell engager that binds gp100 on uveal melanoma cells to initiate an immune-mediated anti-tumour response demonstrated a one-year OS benefit of 73% although this therapy is restricted to uveal melanoma patients with HLA-A∗02:01 tumours.14 This evidence concerns the gene PMEL and uveal melanoma.